Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

redpharm drug, inc. - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - diclofenac potassium 50 mg - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation). diclofenac potassium tablets are indicated: • for treatment of primary dysmenorrhea • for relief of mild to moderate pain • for relief of the signs and symptoms of osteoarthritis • for relief of the signs and symptoms of rheumatoid arthritis diclofenac is contraindicated in the following patients: • known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings; anaphylactic reactions, serious skin reactions). • history of asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylact

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - diclofenac sodium 25mg;   - enteric coated tablet - 25 mg - active: diclofenac sodium 25mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide iron oxide yellow lactose monohydrate magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide triethyl citrate - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - diclofenac sodium 50mg;   - enteric coated tablet - 50 mg - active: diclofenac sodium 50mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide iron oxide yellow lactose monohydrate magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide triethyl citrate - treatment of: inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; acute attacks of gout; post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; as an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. fever alone is not an indication.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: magnesium stearate; peg-40 hydrogenated castor oil; iron oxide yellow; hypromellose; purified water; microcrystalline cellulose; sodium starch glycollate type a; colloidal anhydrous silica; triethyl citrate; maize starch; purified talc; titanium dioxide; povidone; lactose monohydrate; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component.,symptomatic treatment of primary dysmenorrhoea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

sigma company limited - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: purified talc; purified water; triethyl citrate; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; peg-40 hydrogenated castor oil; povidone; hypromellose; microcrystalline cellulose; maize starch; iron oxide yellow; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: iron oxide yellow; colloidal anhydrous silica; magnesium stearate; povidone; maize starch; triethyl citrate; sodium starch glycollate type a; purified water; purified talc; titanium dioxide; lactose monohydrate; hypromellose; peg-40 hydrogenated castor oil; microcrystalline cellulose; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: purified talc; povidone; titanium dioxide; sodium starch glycollate type a; triethyl citrate; purified water; maize starch; iron oxide yellow; microcrystalline cellulose; colloidal anhydrous silica; hypromellose; lactose monohydrate; peg-40 hydrogenated castor oil; magnesium stearate; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

medreich australia pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; triethyl citrate; peg-40 hydrogenated castor oil; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate; purified water; titanium dioxide; maize starch; povidone; iron oxide yellow; hypromellose; lactose monohydrate; polysorbate 80; methacrylic acid copolymer; sodium lauryl sulfate - relief of acute pain states in which there is an inflammatory component.,symptomatic treatment of primary dysmenorrhoea.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

apotheca, inc - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - diclofenac potassium 50 mg - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac potassium tablets are indicated: - for treatment of primary dysmenorrhea - for relief of mild to moderate pain - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis diclofenac potassium tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac potassium tablets should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactic reactions and precautions, preexisting asthma ). diclofenac potassium tablets are contraindicated

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

pack pharmaceuticals, llc - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 75 mg - carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). diclofenac sodium delayed-release tablets, are indicated: - for relief of signs and symptoms of osteoarthritis - for relief of signs and symptoms of rheumatoid arthritis - for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis diclofenac sodium delayed-release tablets are contraindicated in patients with known hypersensitivity to diclofenac. diclofenac sodium delayed-release tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, rarely fatal, anaphylactic-like reactions to nsaids have been reported in such patients (see warnings, anaphylactoid reactions , and pre